AV-1451 Imaging for Apraxia of Speech
What You Need to Know Before You Apply
What is the purpose of this trial?
The study is designed to determine the relationship between structural and functional changes in the brain on imaging and progression of speech and language, neurological and neuropsychological features in patients with neurodegenerative apraxia of speech (AOS).
Will I have to stop taking my current medications?
The trial excludes participants who are on medications that might affect brain structure or metabolism, such as chemotherapy. If you are taking such medications, you may need to stop them to participate.
Is AV-1451 (Flortaucipir F 18) safe for use in humans?
Flortaucipir F 18 has been used in studies with patients having various conditions, such as primary progressive apraxia of speech and Alzheimer's disease, without specific safety concerns reported in these studies. However, the studies mainly focus on its effectiveness in tracking disease progression rather than detailed safety evaluations.12345
How does the treatment AV-1451 imaging differ from other treatments for apraxia of speech?
What data supports the effectiveness of the drug AV-1451 (Flortaucipir F 18) for apraxia of speech?
Who Is on the Research Team?
Jennifer Whitwell, PhD
Principal Investigator
Mayo Clinic
Are You a Good Fit for This Trial?
This trial is for individuals diagnosed with neurodegenerative apraxia of speech (AOS) at Mayo Clinic. It's not suitable for those with severe claustrophobia, pregnant or breastfeeding women, people on certain medications like chemotherapy, those with metal implants that affect MRI scans, brain structure abnormalities, or other illnesses causing speech issues.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Imaging and Assessment
Participants undergo Tau PET scan and multi-modality neuroimaging to assess Tau burden and other neurodegenerative markers
Longitudinal Monitoring
Participants are monitored for changes in neuroimaging, speech and language, neurological, and neuropsychological assessments
Follow-up
Participants are monitored for safety and effectiveness after initial assessments
What Are the Treatments Tested in This Trial?
Interventions
- AV-1451
Find a Clinic Near You
Who Is Running the Clinical Trial?
Mayo Clinic
Lead Sponsor
National Institute on Deafness and Other Communication Disorders (NIDCD)
Collaborator